Shares of Novo Nordisk experienced a significant boost following the launch of the first-ever oral GLP-1 medication for obesity in the United States, a pivotal advancement in the weight loss drug market. The new oral version of Wegovy is set to be available at over 70,000 pharmacies nationwide, with retail prices starting at $149 per month. This pricing strategy positions it below the list price of existing injectable GLP-1 therapies, potentially making obesity treatment more accessible to a wider audience.
In the cryptocurrency realm, Bitcoin prices have surged back above $94,000, a movement that analysts interpret as a renewed bullish trend as 2026 begins. A report from crypto research firm 10X indicates that trading volumes are stabilizing and institutional investment is beginning to rebound following a challenging close to 2025. This positive momentum may signal a turning point for the cryptocurrency sector.
Additionally, Qualcomm shares are witnessing an uptick in today’s trading session. The tech giant is generating excitement with the unveiling of new hardware at the Consumer Electronics Show (CES). As Qualcomm seeks to strengthen its foothold in the personal computer and artificial intelligence markets, it also announced a new initiative focused on humanoid robotics. This emerging market is projected to reach a staggering $1 trillion by 2040, highlighting Qualcomm’s commitment to innovation and future growth.
